{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:32:14Z","timestamp":1791894734042,"version":"4.3.4"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0200725","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T17:34:59Z","timestamp":1533144899000},"page":"e0200725","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":31,"title":["The phosphoinositide-3 kinase (PI3K)-\u03b4,\u03b3 inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-160X","authenticated-orcid":true,"given":"Kerrie","family":"Faia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Proctor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Pink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Kosmider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"McGovern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery","family":"Kutok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,8,1]]},"reference":[{"issue":"16","key":"ref1","doi-asserted-by":"crossref","first-page":"10963","DOI":"10.1074\/jbc.274.16.10963","article-title":"Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase","volume":"274","author":"L Bi","year":"1999","journal-title":"J Biol Chem"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1084\/jem.20020805","article-title":"A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation","volume":"196","author":"E Clayton","year":"2002","journal-title":"J Exp Med"},{"issue":"20","key":"ref3","doi-asserted-by":"crossref","first-page":"8559","DOI":"10.1021\/jm300847w","article-title":"PI3K\u03b4 and PI3K\u03b3 as targets for autoimmune and inflammatory diseases","volume":"55","author":"TD Cushing","year":"2012","journal-title":"J Med Chem"},{"issue":"5455","key":"ref4","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1126\/science.287.5455.1049","article-title":"Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation","volume":"287","author":"E Hirsch","year":"2000","journal-title":"Science"},{"issue":"168","key":"ref5","doi-asserted-by":"crossref","first-page":"ra23","DOI":"10.1126\/scisignal.2001617","article-title":"PI3K\u03b2 plays a critical role in neutrophil activation by immune complexes","volume":"4","author":"S Kulkarni","year":"2011","journal-title":"Sci Signal"},{"key":"ref6","first-page":"256","article-title":"Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies","volume":"3","author":"KD Puri","year":"2012","journal-title":"Front Immunol"},{"issue":"9","key":"ref7","first-page":"5673","article-title":"Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses","volume":"183","author":"CA Durand","year":"2009","journal-title":"J Immunol Baltim Md 1950"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1084\/jem.20070763","article-title":"PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation","volume":"205","author":"C Guiducci","year":"2008","journal-title":"J Exp Med"},{"key":"ref9","first-page":"1","article-title":"PI3K: from the bench to the clinic and back","volume":"347","author":"B Vanhaesebroeck","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cellsig.2010.10.002","article-title":"Phosphoinositide 3-kinase delta (PI3K\u03b4) in leukocyte signaling and function","volume":"23","author":"W-P Fung-Leung","year":"2011","journal-title":"Cell Signal"},{"issue":"5583","key":"ref11","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1073560","article-title":"Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice","volume":"297","author":"K Okkenhaug","year":"2002","journal-title":"Science"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.18632\/oncotarget.341","article-title":"Phosphoinositide 3\u2019-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia","volume":"2","author":"JA Burger","year":"2011","journal-title":"Oncotarget"},{"issue":"13","key":"ref13","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2019-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"J Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"BJ Lannutti","year":"2011","journal-title":"Blood"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ccr.2012.02.029","article-title":"Targeting nonclassical oncogenes for therapy in T-ALL","volume":"21","author":"PS Subramaniam","year":"2012","journal-title":"Cancer Cell"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.chembiol.2013.09.017","article-title":"PI3K-\u03b4 and PI3K-\u03b3 inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models","volume":"20","author":"DG Winkler","year":"2013","journal-title":"Chem Biol"},{"issue":"21","key":"ref17","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1182\/blood.V120.21.3663.3663","article-title":"Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-\u03b4,\u03b3, in Patients with Advanced Hematologic Malignancies","volume":"120","author":"IW Flinn","year":"2015","journal-title":"Blood"},{"issue":"21","key":"ref18","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1182\/blood.V124.21.3334.3334","article-title":"Duvelisib (IPI-145), a PI3K-\u03b4,\u03b3 Inhibitor, Is Clinically Active in Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia","volume":"124","author":"S O\u2019Brien","year":"2014","journal-title":"Blood"},{"issue":"21","key":"ref19","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1182\/blood.V122.21.1832.1832","article-title":"The Potent PI3K-\u03b4,\u03b3 Inhibitor IPI-145 Exhibits Differential Activity In Diffuse Large B-Cell Lymphoma (DLBCL) Cell Lines","volume":"122","author":"V Campbell","year":"2013","journal-title":"Blood"},{"issue":"5712","key":"ref20","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"DD Sarbassov","year":"2005","journal-title":"Science"},{"issue":"1","key":"ref21","first-page":"19","article-title":"Physiological regulation of Akt activity and stability","volume":"2","author":"Y Liao","year":"2010","journal-title":"Am J Transl Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3389\/fonc.2013.00165","article-title":"The Paradox of Akt-mTOR Interactions","volume":"3","author":"L Vadlakonda","year":"2013","journal-title":"Front Oncol"},{"issue":"9","key":"ref23","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/leu.2015.105","article-title":"The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K\/AKT\/S6 pathway and promotes apoptosis in CLL","volume":"29","author":"K Balakrishnan","year":"2015","journal-title":"Leukemia"},{"issue":"24","key":"ref24","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2014-07-587279","article-title":"IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells","volume":"124","author":"S Dong","year":"2014","journal-title":"Blood"},{"key":"ref25","article-title":"Inhibition of the PI3K\/AKT\/mTOR Pathway in Solid Tumors","author":"PM LoRusso","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0200725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T16:25:19Z","timestamp":1661703919000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0200725"}},"subtitle":[],"editor":[{"given":"Ferenc","family":"Gallyas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0200725","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,1]]}}}